FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566158785> ?p ?o ?g. }

• W1566158785 endingPage "6551" @default.
• W1566158785 startingPage "6540" @default.
• W1566158785 abstract "// Boh-Ram Kim 1,* , Kyungsil Yoon 1,* , Hyun-Jung Byun 1 , Seung Hee Seo 1 , Seung-Hoon Lee 2 and Seung Bae Rho 1 1 Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea 2 Department of Life Science, Yong In University, 470, Samga-dong, Cheoin-gu, Yongin-si Gyeonggi-do, Republic of Korea * These Authors contributed equally to this work Correspondence: Seung Bae Rho, email: // Keywords : sMEK1 anti-activator; cell cycle arrest; caspase activity; traditional chemotherapeutic agent; ovarian cancer Received : May 13, 2014 Accepted : June 17, 2014 Published : June 19, 2014 Abstract Recently, we found that sMEK1 effectively regulates pro-apoptotic activity when combined with a traditional chemotherapeutic drug. Therefore, combinational therapeutic strategies targeting critical molecular and cellular mechanisms are urgently required. In this present work, we evaluated whether sMEK1 enhanced the pro-apoptotic activity of chemotherapeutic drugs in ovarian carcinoma cells. Combined with a chemotherapeutic drug, sMEK1 showed an additive effect on the suppression of ovarian cancer cell growth by inducing cell cycle arrest and apoptosis and regulating related gene expression levels or protein activities. In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway was strongly inhibited by the combined treatment, showing de-repression of the tuberous sclerosis complex (TSC) and suppression of ras homolog enriched in the brain (Rheb) and mTOR and raptor in aggressive ovarian carcinoma cells and mouse xenograft models. Treatment with sMEK1 and paclitaxel reduced phosphorylation of ribosomal S6 kinase (S6K) and 4E-binding protein (4E-BP), two critical downstream targets of the mTOR-signaling pathway. Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), both in vitro and in vivo . Therefore, our data suggest that the combination of sMEK1 and paclitaxel is a promising and effective targeted therapy for chemotherapy-resistant or recurrent ovarian cancers." @default.
• W1566158785 created "2016-06-24" @default.
• W1566158785 creator A5025012077 @default.
• W1566158785 creator A5034172710 @default.
• W1566158785 creator A5034210092 @default.
• W1566158785 creator A5050841050 @default.
• W1566158785 creator A5072445975 @default.
• W1566158785 creator A5079451354 @default.
• W1566158785 date "2014-06-19" @default.
• W1566158785 modified "2023-10-17" @default.
• W1566158785 title "The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways" @default.
• W1566158785 cites W1590358247 @default.
• W1566158785 cites W1595815978 @default.
• W1566158785 cites W1963871367 @default.
• W1566158785 cites W1964012705 @default.
• W1566158785 cites W1968437779 @default.
• W1566158785 cites W1971967721 @default.
• W1566158785 cites W1990797251 @default.
• W1566158785 cites W1995197723 @default.
• W1566158785 cites W1996914249 @default.
• W1566158785 cites W2005496215 @default.
• W1566158785 cites W2006559495 @default.
• W1566158785 cites W2007029984 @default.
• W1566158785 cites W2007456673 @default.
• W1566158785 cites W2008257691 @default.
• W1566158785 cites W2011810742 @default.
• W1566158785 cites W2015173256 @default.
• W1566158785 cites W2030092320 @default.
• W1566158785 cites W2042121553 @default.
• W1566158785 cites W2047578735 @default.
• W1566158785 cites W2050988292 @default.
• W1566158785 cites W2051003586 @default.
• W1566158785 cites W2053217945 @default.
• W1566158785 cites W2057909786 @default.
• W1566158785 cites W2076082087 @default.
• W1566158785 cites W2081593830 @default.
• W1566158785 cites W2084533871 @default.
• W1566158785 cites W2092697205 @default.
• W1566158785 cites W2093178422 @default.
• W1566158785 cites W2103154710 @default.
• W1566158785 cites W2114801527 @default.
• W1566158785 cites W2129585918 @default.
• W1566158785 cites W2135794081 @default.
• W1566158785 cites W2152600551 @default.
• W1566158785 cites W2155045727 @default.
• W1566158785 cites W2162740250 @default.
• W1566158785 cites W2321053393 @default.
• W1566158785 doi "https://doi.org/10.18632/oncotarget.2119" @default.
• W1566158785 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4171649" @default.
• W1566158785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25153728" @default.
• W1566158785 hasPublicationYear "2014" @default.
• W1566158785 type Work @default.
• W1566158785 sameAs 1566158785 @default.
• W1566158785 citedByCount "18" @default.
• W1566158785 countsByYear W15661587852015 @default.
• W1566158785 countsByYear W15661587852016 @default.
• W1566158785 countsByYear W15661587852017 @default.
• W1566158785 countsByYear W15661587852018 @default.
• W1566158785 countsByYear W15661587852019 @default.
• W1566158785 countsByYear W15661587852020 @default.
• W1566158785 countsByYear W15661587852021 @default.
• W1566158785 countsByYear W15661587852022 @default.
• W1566158785 countsByYear W15661587852023 @default.
• W1566158785 crossrefType "journal-article" @default.
• W1566158785 hasAuthorship W1566158785A5025012077 @default.
• W1566158785 hasAuthorship W1566158785A5034172710 @default.
• W1566158785 hasAuthorship W1566158785A5034210092 @default.
• W1566158785 hasAuthorship W1566158785A5050841050 @default.
• W1566158785 hasAuthorship W1566158785A5072445975 @default.
• W1566158785 hasAuthorship W1566158785A5079451354 @default.
• W1566158785 hasBestOaLocation W15661587851 @default.
• W1566158785 hasConcept C104202773 @default.
• W1566158785 hasConcept C105696609 @default.
• W1566158785 hasConcept C121608353 @default.
• W1566158785 hasConcept C126322002 @default.
• W1566158785 hasConcept C170493617 @default.
• W1566158785 hasConcept C190283241 @default.
• W1566158785 hasConcept C2777292972 @default.
• W1566158785 hasConcept C2778937405 @default.
• W1566158785 hasConcept C2780427987 @default.
• W1566158785 hasConcept C2780926556 @default.
• W1566158785 hasConcept C29537977 @default.
• W1566158785 hasConcept C502942594 @default.
• W1566158785 hasConcept C54355233 @default.
• W1566158785 hasConcept C55493867 @default.
• W1566158785 hasConcept C62112901 @default.
• W1566158785 hasConcept C62478195 @default.
• W1566158785 hasConcept C71924100 @default.
• W1566158785 hasConcept C75217442 @default.
• W1566158785 hasConcept C86554907 @default.
• W1566158785 hasConcept C86803240 @default.
• W1566158785 hasConcept C88045685 @default.
• W1566158785 hasConcept C95444343 @default.
• W1566158785 hasConcept C98490376 @default.
• W1566158785 hasConceptScore W1566158785C104202773 @default.
• W1566158785 hasConceptScore W1566158785C105696609 @default.
• W1566158785 hasConceptScore W1566158785C121608353 @default.
• W1566158785 hasConceptScore W1566158785C126322002 @default.

• next